|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.955 SEK | +2.25% |
|
-26.12% | -61.42% |
| Apr. 15 | Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain | CI |
| Apr. 04 | Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024 | CI |
Oncopeptides AB (publ) reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was SEK 35.22 million compared to SEK 8.36 million a year ago. Net loss was SEK 249.11 million compared to SEK 337.95 million a year ago.
Basic loss per share from continuing operations was SEK 2.76 compared to SEK 4.11 a year ago. Diluted loss per share from continuing operations was SEK 2.76 compared to SEK 4.11 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -61.42% | 26.62M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
ONCOPEPTIDES AB 
